Gsa Capital Partners LLP Hepion Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.93 - $1.29 $19,117 - $26,517	-20,556 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.14 - $1.58 $23,433 - $32,478	20,556 New	20,556 $23,000
Q2 2021 Aug 05, 2021	SELL	$1.56 - $2.26 $250,809 - $363,351	-160,775 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$1.77 - $2.98 $126,923 - $213,689	71,708 Added 80.51%	160,775 $296,000
Q4 2020 Feb 03, 2021	BUY	$1.58 - $3.64 $140,725 - $324,203	89,067 New	89,067 $195,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.